Musílek Kamil

Info KM aj

For Czech version click here

Group leader
+420 495 833 885
kamil.musilek@fnhk.cz
ORCID: 0000-0002-7504-4062


 

Education

prof.

assoc. prof.

(2019)

(2012)

Charles University, Faculty of Pharmacy in Hradec Kralove, branch Pharmaceutical chemistry

Charles University, Faculty of Pharmacy in Hradec Kralove, branch Pharmaceutical chemistry
PharmDr. (2008) Charles University, Faculty of Pharmacy in Hradec Kralove, branch Pharmaceutical chemistry
Ph.D. (2007) Charles University, Faculty of Pharmacy in Hradec Kralove, branch Pharmaceutical chemistry
MSc. (2004) Charles University, Faculty of Pharmacy in Hradec Kralove, branch Pharmacy


Research focus

  • bioorganic, medicinal or pharmaceutical chemistry, toxicology
  • synthesis of novel bioactive compounds
  • evaluation of novel bioactive compounds
  • molecular modelling of bioactive compounds and mapping of the enzyme or receptor interactions
  • structure-activity relationship of bioactive compounds


Professional Training

since 2019
since 2011		 Senior researcher, Biomedical Research Center (BRC), University Hospital Hradec Kralove
Head of department, University of Hradec Kralove, Faculty of Science, Department of
2011–2018 Head of chemistry lab, Biomedical Research Center (BRC), University Hospital Hradec Kralove
2006–2011 Head of chemistry lab, University of Defence, Faculty of Military Health Sciences, Department of Toxicology
2004–2007 Ph.D. student


International Experience

2009 Centre Recherche Service Santé Armée, La Tronche/Grenoble, Francie (2 months)
2007 University of St. Andrews, Skotsko (6 months)
2003–2004 Ruprecht-Karls-Universität Heidelberg, Německo (5 months)


Membership

  • CZ Pharmaceutical Society (2004)
  • CZ Chemical Society (2005)
  • CZ Society for Experimental and Clinical Pharmacology and Toxicology (2009)


Scientific project solution

GA21-03000S (2021-2023), GA19-13628S (2019-2021), GA18-01734S (2018-2020), GA18-14259S (2018-2020), NV16-34390A (2016-2019), NV15-28967A (2015-2018), LD14009 (2014-2015), LH13009 (2013-2015), ME09086 (2009-2012), GP203/09/P130 (2009-2011), OVUOFVZ200805 (2008-2011)


International cooperation

  • Bundeswehr Institute of Pharmacology and Toxicology, Germany
  • Consejo Superior de Investigaciones Cientificas (CSIC) Madrid, Spain
  • Florida International University, Miami, USA
  • Institut de Recherche Biomedicale des Armees (IRBA), Bretigny-sur-Orge, France
  • Institute for Medical Research and Occupational Health, Croatia
  • Jagiellonian University Medical College Krakow, Poland
  • Korea Research Institute of Chemical Technology, Republic of Korea
  • Semmelweis University, Faculty of Pharmacy, Hungary
  • University Bourgogne Franche-Comte, Besancon, France
  • University of St. Andrews, School of Biology, United Kingdom

Student supervision and educational activities

postgraduate students 5 finished, 6 in progress
pregraduate students 15 finished
lectures Bioorganic chemistry, Medicinal Chemistry, Organic chemistry, Toxicology

Awards

  • 2nd-3rd place EFMC Prize for a Young Medicinal Chemist in Academia (2019)
  • among 10-most cited articles published in Chem. Pap. up-to 2011 (2011)
  • co-author of 4th most cited paper in Mini-Rev. in Med. Chem. in 2010 (2011)
  • among Top 50-most cited articles published in Bioorganic and Medicinal Chemistry Letters 2006-2009 (2010) and 2005-2008 (2009)
  • Medal Faculty of Pharmacy Charles University for excellent faculty representation and development (2010)
  • Prize of Dean Faculty of Military Health Sciences University of Defence for research activities in 2008 (2009)
  • Prize of Czech Ministry of Education, Youth and Sports 2008 for excellent post-graduate students (2008)
  • 1st place Prix de Pharmacie 2008 by Sanofi-Aventis and French Embassy in the Czech Republic (2008)
  • Chevening scholarship 2006/2007 (6 months internship, Scotland, St. Andrews)

 

Publication activity

  • Author or co-author of more than 200 scientific articles in journals indexed by Web of Knowledge
  • Author or co-author of 13 chapters in monograph
  • Author or co-author of 5 patents
  • H-index: 32 (dated 04/2020)

 

Selected Publications

2021

Deng, Y.; You, L.; Nepovimova, E.; Wang, X.; Musilek, K.; Wu, Q.*; Wu, W.*; Kuca, K.* Biomarkers of Deoxynivalenol (DON) and Its Modified Form DON-3-Glucoside (DON-3G) in Humans. Trends in Food Science & Technology. 2021, vol. 110, no. 1, p. 551-558. DOI: 10.1016/j.tifs.2021.02.038. IF2019 = 11.077

Lee, H.M; Andrys, R.; Jonczyk, J.; Kim, K.; Vishakantegowda, A.G.; Malinak, D.; Skarka, A.; Schmidt, M.; Vaskova, M.; Latka, K.; Bajda, M.; Jung, Y.S.*; Malawska, B.*; Musilek, K.* Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates. Journal of Enzyme Inhibition and Medicinal Chemistry. 2021, vol. 36, no. 1, p. 437–449. DOI: 10.1080/14756366.2020.1869954. IF2019 = 4.673

Handl, J.; Malinak, D.; Capek, J.; Andrys, R.; Rousarova, E.; Hauschke, M.; Bruckova, L.; Cesla, P.; Rousar, T.*; Musilek, K.* Effects of charged oxime reactivators on the HK-2 cell line in renal toxicity screening. Chemical Research in Toxicology. 2021, vol. 34, no. 3, p. 699-703. DOI: 10.1021/acs.chemrestox.0c00489. IF2019 = 3.184

2020

Juza, R.; Vlcek, P.; Mezeiova, E.; Musilek, K.; Soukup, O.*; Korabecny, J.* Recent Advances with 5-HT3 Modulators for Neuropsychiatric and Gastrointestinal Disorders. Medicinal Research Reviews. 2020, vol. 40, no. 5, p. 1593-1678. DOI: 10.1002/med.21666. IF2019 = 9.300

Gorecki, L.; Andrys, R.; Schmidt, M.; Kucera, T.; Psotka, M.; Svobodova, B.; Hrabcova, V.; Hepnarova, V.; Bzonek, P.; Jun, D.; Kuca, K.; Korabecny, J.*; Musilek, K.* Cysteine-Targeted Insecticides against A. gambiae Acetylcholinesterase are neither Selective nor Reversible Inhibitors. ACS Medicinal Chemistry Letters. 2020, vol. 11, no. 1, p. 65-71. DOI: 10.1021/acsmedchemlett.9b00477. IF2018 = 3.737

Vinklarova, L.; Schmidt, M.*; Benek, O.; Kuca, K.; Gunn-Moore, F.; Musilek, K.* Friend or enemy? Review of 17β-HSD10 and its role in human health or disease. Journal of Neurochemistry. 2020, in press. DOI: 10.1111/jnc.15027. IF2018 = 4.870

2019

Gorecki, L.; Soukup, O.; Kucera, T.; Malinak, D.; Jun, D.; Kuca, K.; Musilek, K.*; Korabecny, J.* Oxime K203: a drug candidate for the treatment of tabun intoxication. Archives of Toxicology. 2019, vol. 93, no. 3, p. 673-691. DOI: 10.1007/s00204-018-2377-7. IF2018 = 5.741

Salajkova, S.; Sramek, M.; Malinak, D.; Havel, F.; Musilek, K.; Benkova, M.; Soukup, O.; Vasicova, P.; Prchal, L.; Dolezal, R.; Hodny, Z.; Bartek, J.; Zarska, M.*; Kuca, K.* Highly hydrophilic cationic gold nanorods stabilized by novel quaternary ammonium surfactant with negligible cytotoxicity. Journal of Biophotonics. 2019, vol. 12, no. 12, p. e201900024. DOI: 10.1002/jbio.201900024. IF2018 = 3.763

Zorbaz, T.; Malinak, D.; Kuca, K.; Musilek, K.*; Kovarik, Z.* Butyrylcholinesterase inhibited by nerve agents is efficiently reactivated with chlorinated pyridinium oximes. Chemico-Biological Interactions. 2019, vol. 307, no. 1, p. 16-20. DOI: 10.1016/j.cbi.2019.04.020. IF2018 = 3.407

2018

Zarska, M.; Sramek, M.; Novotny, F.; Havel, F.; Babelova, A; Mrazkova, B.; Benada, O.; Reinis, M.; Stepanek, I.; Musilek, K.; Bartek, J.; Ursinyova, M.; Novak, O.; Dzijak, R.; Kuca, K.*; Proska, J.*; Hodny, Z.* Biological safety and tissue distribution of (16-mercaptohexadecyl)trimethylammonium bromide-modified cationic gold nanorods. Biomaterials 2018, vol. 154, no. 1, p. 275-290. DOI: 10.1016/j.biomaterials.2017.10.044. IF2016 = 8.402

2017

Zdarova Karasova, J.*; Kvetina, J.; Tacheci, I.; Radochova, V.; Musilek, K.; Kuca, K.; Bures, J. Pharmacokinetic profile of promising acetylcholinesterase reactivators K027 and K203 in experimental pigs. Toxicology Letters 2017, vol. 273, no. 1, p. 20-25. DOI: 10.1016/j.toxlet.2017.03.017. IF2016 = 3.858

2016

Benek, O.; Soukup, O.; Pasdiorova, M.; Hroch, L.; Sepsova, V.; Jost, P.; Hrabinova, M.; Jun, D.; Kuca, K.; Zala, D.; Ramsay, R.R.; Marco-Contelles, J.*; Musilek, K.* Design, synthesis and in vitro evaluation of indolotacrine analogues as multi-target-directed ligands for the treatment of Alzheimer’s disease. ChemMedChem, 2016, vol. 11, no. 12, p. 1264-1269. DOI: 10.1002/cmdc.201500383. IF2016 = 3.225 

2015

Horn, G.; Wille, T.; Musilek, K.; Kuca, K.; Thiermann, H.; Worek, F.* Reactivation kinetics of 31 structurally different bispyridinium oximes with organophosphate-inhibited human butyrylcholinesterase. Archives of Toxicology. 2015, vol. 89, no. 3, p. 405–414. DOI: 10.1007/s00204-014-1288-5. IF2015 = 6.637 

2014

Misik, J.*; Vanek, J.; Musilek, K.; Kassa, J. Cholinergic antagonist 3-quinuclidinyl benzilate; impact on learning and memory in Wistar rats. Behavioural Brain Research. 2014, vol. 266, no. 1, p. 193-200. DOI: 10.1016/j.bbr.2014.03.001. IF2014 = 3.028 

2013

Kalasz, H. – Szegi, P. – Janoki, G. – Balogh, L. – Postenyi, Z. – Musilek, K. – Petroianu, G.A. – Siddiq, A. - Tekes, K. Study on Medicinal Chemistry of K203 in Wistar Rats and Beagle Dogs. Current Medicinal Chemistry. 2013, 20(16), p. 2137-2144. DOI: 10.2174/0929867311320160006. IF2011 = 4.859 

2012

Worek, F. - von der Wellen. J. - Musilek, K. - Kuca, K. - Thiermann, H. Reactivation kinetics of a homologous series of bispyridinium bis-oximes with nerve agent-inhibited human acetylcholinesterase. Archives of Toxicology. 2012, 86(9), p. 1379-1386. DOI: 10.1007/s00204-012-0842-2. IF2011 = 4.674 

2011

Musilek, K. - Dolezal, M. - Gunn-Moore, F. - Kuca, K. Design, Evaluation and Structure-Activity Relationship Studies of the AChE Reactivators Against Organophosphorus Pesticides. Medicinal Research Reviews. 2011, 31(4), p. 548-575. DOI: 10.1002/med.20192. IF2011 = 10.700 

2010

Muirhead, K. E. A. - Froemming, M. - Li, X. G. - Musilek, K. - Conway, S. J. - Sames, D. - Gunn-Moore, F. J. (-)-CHANA, a Fluorogenic Probe for Detecting Amyloid Binding Alcohol Dehydrogenase HSD10 Activity in Living Cells. ACS Chemical Biology. 2010, 5(12), p. 1105-1114. DOI: 10.1021/cb100199m. IF2010 = 5.698 

2009

Jeong, H. C. - Park, N. J. - Chae, C. H. - Musilek, K. - Kassa, J. - Kuca, K. - Jung, Y. S. Fluorinated pyridinium oximes as potential reactivators for acetylcholinesterases inhibited by paraoxon organophosphorus agent. Bioorganic & Medicinal Chemistry. 2009, 17(17), p. 6213-6217. DOI: 10.1016/j.bmc.2009.07.043 IF2009 = 2.822 

2008

Musilek, K. - Jampilek, J. - Dohnal, J. - Jun, D. - Gunn-Moore, F. - Dolezal, M. - Kuca, K. RP-HPLC determination of the lipophilicity of bispyridinium reactivators of acetylcholinesterase bearing a but-2-ene connecting linker. Analytical and Bioanalytical Chemistry. 2008, 391(1), p. 367-372. DOI: 10.1007/s00216-008-2018-8. IF2008 = 3.328 

2007

Musilek, K. - Jun, D. - Cabal, J. - Kassa, J. - Gunn-Moore, F. - Kuca, K. Design of a potent reactivator of tabun-inhibited acetylcholinesterase-synthesis and evaluation of (E)-1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)-but-2-ene dibromide (K203). Journal of Medicinal Chemistry. 2007, 50(22), p. 5514-5518. DOI: 10.1021/jm070653r. IF2007 = 4.895 

2006

Musilek, K. - Kuca, K. - Jun, D. - Dohnal, V. - Dolezal, M. Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase. Bioorganic & Medicinal Chemistry Letters. 2006, 16(3), p. 622-627. DOI:10.1016/j.bmcl.2005.10.059. IF2006 = 2.538 

2005

Fiammengo, R. - Musilek, K. - Jaschke, A. Efficient preparation of organic substrate-RNA conjugates via in vitro transcription. Journal of the American Chemical Society. 2005, 127(25), p. 9271-9276. DOI: 10.1021/ja051179m. IF2005 = 7.419